[Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
XELOX for unresectable advanced colorectal cancer has been approved in Japan. We report here an experience of the treatment with XELOX±bevacizumab in our department. We thought that the regimen has some merits in the patient's quality of life. Forty-five patients were treated with XELOX±bevacizumab. In evaluable 23 cases, partial response (PR) was obtained in 13 cases and stable disease (SD) and progressive disease (PD) were in 5 and 5 cases, so that the response rate and disease control rate were 56.5% and 78.2%, respectively. In the first-line administration of 19 cases, the response rate and disease control rate were respectively 80.0% and 90.0%. Hand-foot syndrome was observed in 13.2% (grade 2) and 6 .6% (grade 3). We think that it is important to control hand-foot syndrome for a continuation of XELOX±bevacizumab.
Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
Shinichiro
S
Kashiwagi
Kiyoshi
K
Maeda
Yuhiko
Y
Fuyuhiro
Hisashi
H
Nagahara
Kenjiro
K
Kimura
Ryosuke
R
Amano
Eiji
E
Noda
Naoshi
N
Kubo
Hiroaki
H
Tanaka
Kazuya
K
Muguruma
Masakazu
M
Yashiro
Nobuya
N
Yamada
Bunzo
B
Nakata
Masaichi
M
Ohira
Tetsuro
T
Ishikawa
Kosei
K
Hirakawa
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010071:Oxaloacetates
D061067:Antibodies, Monoclonal, Humanized; D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil